{"entity":{"id":"pfl-721","kind":"drug","name":"PFL-721","aka":["STX-721"],"tldr":"PFL-721 is an experimental small molecule kinase inhibitor from Antares Therapeutics, in phase 1 trials for non-small cell lung cancer with EGFR or HER2 exon 20 insertion mutations.","summary":"PFL-721 (STX-721) is a small molecule kinase inhibitor from Antares Therapeutics, with Pierre Fabre Laboratories as licensee and Scorpion Therapeutics as partner. A mutant-specific inhibitor of EGFR exon 20 and HER2 exon 20 insertion mutations. Its furthest stage is phase 1, for non-small cell lung cancer with EGFR or HER2 exon 20 insertion mutations. ClinicalTrials.gov registers it in one study linked below. First-in-human phase 1/2 NCT06043817 recruiting, sponsored by Pierre Fabre Medicament. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Antares Therapeutics: biospace.com","url":"https://www.biospace.com/press-releases/pierre-fabre-laboratories-strengthen-r-d-portfolio-and-announce-the-acquisition-of-the-worldwide-rights-for-pfl-721-and-pfl-241"},{"label":"Antares Therapeutics: biospace.com","url":"https://www.biospace.com/press-releases/pierre-fabre-laboratories-strengthen-r-d-portfolio-and-announce-the-acquisition-of-the-worldwide-rights-for-pfl-721-and-pfl-241"},{"label":"Antares Therapeutics: antaresrx.com","url":"https://antaresrx.com/"},{"label":"Antares Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT06043817"},{"label":"ClinicalTrials.gov: trials of PFL-721","url":"https://clinicaltrials.gov/search?intr=PFL-721"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":["egfr","her2"],"drugs":[],"companies":["antares-therapeutics","pierre-fabre"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06043817"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"PFL-721","modality":"Small molecule kinase inhibitor","mechanism":"A mutant-specific inhibitor of EGFR exon 20 and HER2 exon 20 insertion mutations.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/pfl-721/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}],"company":[{"id":"antares-therapeutics","kind":"company","name":"Antares Therapeutics","route":"/companies/antares-therapeutics/"},{"id":"pierre-fabre","kind":"company","name":"Pierre Fabre","route":"/companies/pierre-fabre/"}],"trial":[{"id":"nct06043817","kind":"trial","name":"First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations","route":"/trials/nct06043817/"}]}}